InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
3
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+177.4%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by GERAGHTY JAMES A, Directeur. Insider active across 3 companies, notably Fulcrum Therapeutics, Inc.. Cumulatively, 5 disclosures have been logged. Split: 3 buys · 0 sell. Total volume traded: €154k. Activity tracked since 28 June 2021. The latest transaction was disclosed on 12 December 2024 (Disposition). Regulator: SEC (Form 4). The full history is openly available.
Declarations5 total
1 shares@ US$0.011.0% of flowSeries F Preferred Stock, par value $0.001 per shareSEC:0001437749-24-037353:0
1 shares@ US$1.0099.0% of flowSeries F Preferred Stock, par value $0.001 per shareSEC:0001437749-24-032319:0
Ideal exit: 4 May 2025 (T+270)
44,391 sharesOrdinary SharesSEC:0000950170-24-007087:0
10,000 shares@ US$9.1650.0% of flowCommon StockSEC:0000899243-21-026552
Ideal exit: 25 Mar 2022 (T+270)
10,000 shares@ US$9.160.017% mcap50.0% of flowCommon StockSEC:0000899243-21-026552:0
Ideal exit: 25 Mar 2022 (T+270)
5 of 5 declarations
About GERAGHTY JAMES A
James A. Geraghty is a Director at Fulcrum Therapeutics, Inc. He plays a key role in the governance of the company, bringing his experience to strengthen its strategy.
